We are excited to invite you to an exclusive live webinar featuring Wendy Kirkland, a renowned expert in high-probability options trading. Join us as she shares her insights and strategies in her presentation,
In this informative session, Wendy will discuss her high-probability option tactics, revealing how to identify market patterns and turn them into profitable opportunities. Whether you're a beginner or an experienced trader, you’ll gain valuable knowledge to enhance your trading strategies.
Spots are limited, so don’t miss this opportunity to learn from one of the best in the business!
The US FDA is preparing to roll out a generative AI model to help with scientific reviews across the agency. Plus, according to US FDA Commissioner Marty Makary the tool will be deployed across the agency by the end of June.
We also have to consider that AI in healthcare was valued at about $26.69 billion in 2024, and at about $39.96 billion in 2025. By 2034, it’s expected to be valued at about $613.81 billion, according to Precedence Research.
As also noted by Precedence Research:
With the ability to process and analyze massive amounts of data, AI is revolutionizing patient care, clinical trials, drug discovery, and administrative tasks. From diagnostic tools to personalized treatments, AI technology is helping healthcare professionals make more informed decisions faster.
In addition, by using artificial intelligence, the company can help accelerate drug discovery, shorten the development process, reduce costs and identify more effective treatments.
That should have a positive impact on stocks like Recursion Pharmaceuticals (RXRX).
Most recently, RXRX achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseases, as noted in its earnings release.
An option contract holder is bestowed with three choices – exercise the option, let the option expire, or trade the option. But how does a trader decide which of the three alternatives to choose? A large portion of this decision is contingent upon the value of the option contract (or lack thereof) as well as the amount of time remaining before the option expires. When an option lacks value, meaning it is out-of-the-money, the trader can simply let the option expire worthless. When an option has value, meaning it is in-the-money, the trader can choose whether to trade the contract to another individual or exercise the contract and obtain the underlying asset. The ultimate decision that is made depends upon the individual investor, his or her trading style, trading needs, and the situation at hand.
Exercise the Option
As we just mentioned, one will only exercise a long option contract when one stands to make money from that position, otherwise one could simply let the option expire and lose the premium. (Please Note: There are instances in which this is not necessarily the case, such as when an investor is exercising a large quantity in an illiquid market, but such cases are rare).
Elite Wall Street trader, Joe Duffy, is allowing a limited group of future-elite investors into his masterful daily trades at thousands of dollars less than what others charge.
When you join today for $1, the first month you'll receive:
Joe Duffy’s daily video newsletter with updates on what's happening in the markets that very day. Rather than watch talking heads for hours on cable, I'll get you up to speed in minutes.
You get weekend updates where I delve more into 'bigger picture' looks at the marketplace. Videos are illustrative, instructive, concise, and un-hedged. No double talk here.
PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading.
1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis.
2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services.
3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber.
4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more.
5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities.
6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown.
7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses.
8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.